← Back to headlines
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy
11 Mar, 01:01 — 11 Mar, 01:01
Sources
Showing 1 of 1 sources
Related Stories
SC directs Centre to frame no-fault compensation policy for serious adverse events post COVID-19 vaccination
10m ago
Why a PIL wants victims of forceful acid ingestion recognised under the disability law
24m ago
HPV vaccination drive: Delhi sees only 285 jabs in first 10 days, officials blame exams exams for low turnout
1h ago
Millennial Men Face Low Testosterone Crisis, Doctors Warn
1h ago